The Canaccord Genuity Lowers Merus Labs International Inc (MSLI) to Hold

The Canaccord Genuity Lowers Merus Labs International Inc (MSLI) to Hold

Several other research analysts have also issued reports on the stock. Zacks Investment Research upgraded shares of Merus Labs International from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 18th. Bloom Burton reiterated a “hold” rating on shares of Merus Labs International in a research note on Monday, February 13th. Seven analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $3.88.

Merus Labs International Inc (NASDAQ:MSLI) (TSE:MSL) was downgraded by investment analysts at Canaccord Genuity to a “hold” rating in a note issued to investors on Thursday, May 11th. They presently have a $1.65 price objective on the stock. Canaccord Genuity’s price target would suggest a potential upside of 38.66% from the company’s current price.

Shares of Merus Labs International (NASDAQ:MSLI) opened at 1.19 on Thursday. Merus Labs International has a 52-week low of $0.70 and a 52-week high of $1.35. The company has a 50 day moving average of $0.97 and a 200-day moving average of $0.89. The company’s market cap is $139.65 million.

Hedge funds have recently made changes to their positions in the company. K.J. Harrison & Partners Inc bought a new stake in shares of Merus Labs International during the first quarter worth approximately $190,000. TD Asset Management Inc. increased its position in Merus Labs International by 7.9% in the first quarter. TD Asset Management Inc. now owns 292,527 shares of the company’s stock worth $272,000 after buying an additional 21,507 shares during the last quarter. Finally, Acadian Asset Management LLC increased its position in Merus Labs International by 3.0% in the first quarter. Acadian Asset Management LLC now owns 4,436,536 shares of the company’s stock worth $4,125,000 after buying an additional 127,530 shares during the last quarter. Hedge funds and other institutional investors own 23.09% of the company’s stock. Merus Labs International Company Profile

Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:MSLI”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment